Bristol-Myers Squibb Company (BMY)
Health Care7 articles
Price chart
Bristol-Myers Squibb Company (BMY) overview
Bristol Myers Squibb is a major pharmaceutical company focused on oncology and immunology. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Bristol-Myers Squibb Company trades on the NYSE under the ticker symbol BMY. As of the most recent market data, the stock was priced around $60.74, up 0.38% on the session, giving Bristol-Myers Squibb Company a market capitalization of roughly $124.04B.
Over the past 52 weeks, BMY has traded between $42.52 and $62.89. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 17.0, a common gauge of how richly the market prices the company's earnings. Bristol-Myers Squibb Company also pays a dividend, currently yielding around 4.16%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch BMY
As one of the larger companies in the Health Care sector, Bristol-Myers Squibb Company is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch BMY for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, Bristol-Myers Squibb Company's size means its share-price moves can also nudge the index as a whole, making BMY a stock that even index investors pay attention to.
Market Mood
Latest BMY news
BMY vs JNJ: Healthcare Revenue Comparison for 2025
In fiscal 2025, Bristol Myers Squibb (BMY) reported revenue of nearly $48.2 billion, a decrease of approximately 0.2% from the previous year, with a net income of roughly $7.1 billion and a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved approximately $94.2 billion in revenue, reflecting an increase of nearly 6% year-over-year, accompanied by a net income of around $26.8 billion and a net margin of 28.5%. BMY's balance sheet showed a debt-to-equity ratio of 2.6 and a current ratio of 1.3, while its free cash flow reached nearly $12.8 billion. These figures underscore the differing financial health and revenue growth trajectories of these two healthcare companies.
Read More: BMY vs JNJ: Healthcare Revenue Comparison for 2025
BMY and JNJ Financials: 2025 Revenue Numbers Declared
For FY 2025, Bristol Myers Squibb (BMY) reported revenue of approximately $48.2 billion, reflecting a slight decline of 0.2% year-over-year, while net income was $7.1 billion, yielding a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved revenue of about $94.2 billion, marking a 6.0% increase, with a net income of nearly $26.8 billion and a net margin of 28.5%. BMY's debt-to-equity ratio stood at 2.6x, while JNJ's was 0.6x, indicating differing financial leverage. Their performance could influence investor strategies given the contrasting growth potential and stability they provide.
Read More: BMY and JNJ Financials: 2025 Revenue Numbers Declared
SCHD Fund Achieves 20% Return with $71.6B Assets and 3.3% Yield
The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a year-to-date price return of 20% and currently yields approximately 3.3%. The fund has $71.6 billion in assets and a low expense ratio of 0.06%. Its top holdings include Bristol Myers Squibb, Lockheed Martin, and Chevron, all recognized as Dividend Aristocrats with strong free cash flow. The balanced weighting of positions helps mitigate risks, reinforcing distribution safety despite recent company-specific challenges.
Read More: SCHD Fund Achieves 20% Return with $71.6B Assets and 3.3% Yield
Bristol Myers (BMY) Uses Claude AI for Drug Discovery Initiative
Bristol Myers Squibb (BMY) announced its partnership with Anthropic to implement the Claude AI model in its drug discovery process. This collaboration aims to enhance efficiency and reduce timelines associated with drug development. The deployment of AI technology exemplifies BMY's commitment to innovation within the pharmaceutical sector. As companies increasingly adopt AI tools, the market could see shifts in research and development dynamics, potentially impacting stock performance.
Read More: Bristol Myers (BMY) Uses Claude AI for Drug Discovery Initiative
Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
Bristol Myers Squibb (BMY) reported Q1 adjusted earnings of $1.58 per share, exceeding analysts' expectations of $1.42, with revenue of $11.49 billion also surpassing the forecast of $10.9 billion. Eliquis, partnered with Pfizer, generated $4.14 billion in sales, an increase of 16% year-over-year. Sales from the growth portfolio rose 12% to $6.23 billion, while sales of Opdivo fell 5% to $2.15 billion. The company reaffirmed its 2026 revenue outlook of $46.0 billion to $47.5 billion and adjusted earnings of $6.05 to $6.35 per share.
Read More: Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
Bristol-Myers Squibb (BMY) Offers Low Volatility and High Yield
Bristol-Myers Squibb Company (BMY) ranks 5th among the best defensive stocks and is recognized for low volatility and high yield. The stock features a beta that is approximately 73% less volatile than the S&P 500. Recent updates include a quarterly dividend of $0.63 per share and a cash payout ratio of about 35%. In the recent quarter, growth products like Camzyos and Sotyktu saw a 10% increase, which strengthens BMY's long-term revenue outlook despite some earnings challenges.
Read More: Bristol-Myers Squibb (BMY) Offers Low Volatility and High Yield
BMY Stock Rating Reiterated at Buy by Guggenheim
Guggenheim has reiterated its 'Buy' rating on Bristol-Myers Squibb (BMY). This endorsement could signal ongoing confidence in the company's stock performance amid its recent market activities. As institutional recommendations often influence investor sentiment, this reaffirmation may encourage additional interest from shareholders. It reflects a strategic outlook towards BMY amidst a competitive biotechnology sector.
Read More: BMY Stock Rating Reiterated at Buy by GuggenheimMore Health Care stocks
Frequently asked questions
Is Bristol-Myers Squibb Company in the S&P 500?
Yes. Bristol-Myers Squibb Company (BMY) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is BMY in?
Bristol-Myers Squibb Company is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest BMY news?
This page collects recent Bristol-Myers Squibb Company (BMY) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Bristol-Myers Squibb Company's stock price?
As of the most recent market data, Bristol-Myers Squibb Company (BMY) traded at approximately $60.74. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company has a market capitalization of roughly $124.04B, based on its most recent share price and shares outstanding.
What is BMY's P/E ratio?
BMY trades at a trailing price-to-earnings ratio of about 17.0. The P/E ratio compares a company's share price to its earnings per share.